Skip to main content
News > News > Francis Kirley Appointed To Bacterial Robotics Business Directorate

Francis Kirley Appointed To Bacterial Robotics Business Directorate

Mr. Kirley will advise on business model and systems toward profitability

CINCINNATI, OH. – May 05, 2014 – Bacterial Robotics is a biotechnology firm.  The Company uses synthetic biology tools in an evolutionary engineering approach to develop bacterial robots, or BactoBotsToday, the Company announced the appointment of Mr. Fran Kirley to its Business Directorate.

The Company is developing unique therapeutic BactoBots.  Mr. Kirley’s healthcare business acumen will provide important guidance to management.

Jason E. Barkeloo, CEO stated, “Fran is a proven business leader.  His ability to synthesize complex models and develop systems focused toward profitability will provide the Company with an edge in the marketplace.”

Mr. Kirley is Founder, President and CEO of Nexion Health, a health operator of 36 SNF facilities in LA, TX and CO.  Mr. Kirley has more than 32 years of Acute and Long Term Healthcare Management experience and is actively involved in all levels of the profession.

Currently, Mr. Kirley serves as the AHCA-PAC Chairman, is a Board Member of the following:  Louisiana Nursing Home Association, Elms College, Massachusetts College of Pharmacy and Health Sciences and also the Warfield Development Center, located in Sykesville, MD. Mr. Kirley is a former AHCA Board and Executive Committee Member and former Board Member of the Texas Health Care Association.

About Bacterial Robotics

An early developer in the emerging synthetic biology industry, Bacterial Robotics has headquarters in Winchester, Ohio (USA), operations in Cincinnati, OH and a laboratory in Covington, KY.  The Company specializes in identifying markets for developing and deploying BactoBots™ and ViruBots™; microscopic organism-based robots that produce, build, sense, and perform functions.

The Company’s products are protected by a proprietary genetics rights management (GeRM™) key system.  The GeRM system is a consumable additive that prevents the BactoBots against theft or release.  The GeRM key consumable enables the Company to gain revenues from licensing the manufacture and distribution of its BactoBots.

Once Bacterial Robotics develops a BactoBot, it creates a go-to-market subsidiary to partner with market expert firms.  Pilus Energy was the Company’s first subsidiary, a wastewater-to-value company.  That subsidiary was merged with Tauriga Sciences, Inc. (OTCQB: TAUG) in January 2014.

For more information on Bacterial Robotics, visit its web site at http://BacterialRobotics.com.

VIEW PRESS RELEASE AS .PDF

Contact 

Jason E. Barkeloo

CEO

+1.513.252.2901

Twitter:  @BactoBot at http://twitter.com/BactoBot

http://BacterialRobotics.com/contact/

info(at)BacterialRobotics.com

 

###

Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.